Targeting HNSCC or mucoepidermoid carcinoma CSCs with IL-6R inhibitor (tocilizumab), small molecule inhibitors of MDM2-p53 interaction (MI-773, APG115), mTOR inhibitors (rapamycin, temsirolimus) reduced the CSC fraction, sensitized tumors to chemotherapy and inhibited tumor progression (26–30). This evidence concerns the gene MDM2 and neoplasm.